Chen Zhiliang, Fu Hong, Fang Jianfeng, Yang Jianhui, Zhu Xin, Cheng Bingxiang, Ding Tiannv
Department of Hepatobiliary Surgery, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.
Endoscopy Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang 312000, P.R. China.
Exp Ther Med. 2021 Mar;21(3):251. doi: 10.3892/etm.2021.9682. Epub 2021 Jan 22.
The study aimed to investigate the preventive and therapeutic significance of octreotide combined with lansoprazole on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and its effects on serum amylase (AMS), inflammatory factors and immune function. A total of 132 patients who underwent ERCP in Shaoxing People's Hospital (Shaoxing, China) were enrolled in the study and allocated into two groups: The study group (octreotide plus lansoprazole, 68 cases) and the control group (octreotide alone, 64 cases). The incidence of PEP and post-ERCP hyperamylasemia (PEH), the concentrations of serum AMS, interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α), as well as the T-lymphocyte population in peripheral blood were detected. The AMS levels in the study group were significantly lower than those in the control group at 6 and 24 h after treatment (P<0.001). The incidence of PEP and PEH, symptom disappearance time and hospital stay in the study group were significantly lower than those in the control group after treatment (P<0.05). The levels of IL-17 and TNF-α in the study group were significantly lower than those in the control group after treatment (all P<0.05). The percentage of CD3, CD4, CD8 cells and the ratio of CD4/CD8 in the study group were significantly higher than those in the control group after treatment (all P<0.05). The results indicated that octreotide combined with lansoprazole reduces AMS levels and the incidence of PEP, alleviates inflammation and improves the immune function.
本研究旨在探讨奥曲肽联合兰索拉唑对内镜逆行胰胆管造影术（ERCP）后胰腺炎（PEP）的防治意义及其对血清淀粉酶（AMS）、炎症因子和免疫功能的影响。绍兴市人民医院（中国绍兴）共132例行ERCP的患者纳入本研究并分为两组：研究组（奥曲肽加兰索拉唑，68例）和对照组（单用奥曲肽，64例）。检测PEP和ERCP后高淀粉酶血症（PEH）的发生率、血清AMS、白细胞介素-17（IL-17）和肿瘤坏死因子-α（TNF-α）的浓度以及外周血T淋巴细胞亚群。治疗后6小时和24小时，研究组的AMS水平显著低于对照组（P<0.001）。治疗后，研究组的PEP和PEH发生率、症状消失时间和住院时间均显著低于对照组（P<0.05）。治疗后，研究组的IL-17和TNF-α水平显著低于对照组（均P<0.05）。治疗后，研究组CD3、CD4、CD8细胞百分比及CD4/CD8比值均显著高于对照组（均P<0.05）。结果表明，奥曲肽联合兰索拉唑可降低AMS水平和PEP发生率，减轻炎症并改善免疫功能。
